Medline ® Abstract for Reference 19
of 'Toxicities associated with checkpoint inhibitor immunotherapy'
19
Ribas A, Butler M, Lutzky J, et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J Clin Oncol 33, 2015 (suppl; abstr 3003)
no abstract available